Key Events This Week
21 Sep: New 52-week high at Rs.1,245 and all-time high close at Rs.1,233.15
21 Sep: Technical momentum shifts to bullish trend
22 Sep: Upgraded to Buy rating by MarketsMOJO
25 Sep: Valuation metrics improve, signalling enhanced price attractiveness
25 Sep: Week closes lower at Rs.1,184.20 (-2.93%)
21 September: New 52-Week and All-Time Highs Mark Early Week Optimism
Strides Pharma Science Ltd began the week on a strong note, hitting a new 52-week high of Rs.1,245 intraday and closing at an all-time high of Rs.1,233.15. This represented a daily gain of 1.39% from the previous close, outperforming the Sensex’s 0.46% rise that day. The stock’s price traded above all key moving averages, signalling robust technical momentum. The bullish MACD and Bollinger Bands indicators on weekly and monthly charts supported this positive trend, while the On-Balance Volume (OBV) confirmed strong buying interest.
Despite some mixed momentum signals from the Relative Strength Index (RSI) and Know Sure Thing (KST) oscillators, the overall technical stance shifted from mildly bullish to bullish. This upgrade was reflected in the stock’s technical grade improvement and was a key factor in the positive price action. Institutional participation was strong, with delivery volumes rising significantly, further underpinning the rally.
22 September: Upgrade to Buy Rating Reinforces Confidence
On 22 September, MarketsMOJO upgraded Strides Pharma’s mojo grade from Hold to Buy, citing strong financials and bullish technicals. The upgrade was driven by consistent profitability, with 12 consecutive quarters of positive results and a peak operating cash flow of ₹702.52 crores. The company’s return on capital employed (ROCE) reached a high of 17.96% for the half-year, reflecting efficient capital utilisation.
Valuation metrics were also attractive, with a low PEG ratio of 0.4 and a price-to-earnings (P/E) ratio of 19 times trailing twelve months (TTM), indicating reasonable pricing relative to earnings growth. Despite some leverage concerns, including a Debt to EBITDA ratio of 1.90 times and increased promoter share pledging at 38.1%, the upgrade highlighted the stock’s improved risk-reward profile amid a challenging market backdrop.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
23 to 25 September: Price Retreat Amid Mixed Technical and Valuation Signals
Following the early-week highs and rating upgrade, Strides Pharma’s stock price faced downward pressure in the latter half of the week. On 23 September, the stock rebounded slightly by 0.81% to Rs.1,225.35, outperforming the Sensex’s 0.56% gain. However, on 24 and 25 September, the stock declined by 1.85% and 1.54% respectively, closing the week at Rs.1,184.20.
This pullback coincided with a broader market correction, as the Sensex fell 1.62% on 24 September before recovering marginally on 25 September. Technical indicators presented a nuanced picture: while MACD and Bollinger Bands remained bullish, the RSI and KST oscillators signalled caution, particularly on monthly charts. The Dow Theory readings also reflected mild bearishness on longer timeframes, suggesting potential consolidation or short-term correction.
On 25 September, valuation metrics improved notably, with the P/E ratio at 19.20 and price-to-book value (P/BV) at 3.57, both favourable compared to sector peers. The enterprise value to EBITDA (EV/EBITDA) ratio stood at 13.47, indicating the stock’s relative discount to more expensive pharmaceutical companies. This enhanced valuation attractiveness was a positive signal amid the price decline, suggesting the stock may be better positioned for future stability.
Curious about Strides Pharma Science Ltd from ? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Daily Price Comparison: Strides Pharma vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-21 | Rs.1,236.90 | +1.39% | 35,787.64 | +0.46% |
| 2026-09-22 | Rs.1,215.55 | -1.73% | 35,672.04 | -0.32% |
| 2026-09-23 | Rs.1,225.35 | +0.81% | 35,870.78 | +0.56% |
| 2026-09-24 | Rs.1,202.70 | -1.85% | 35,291.38 | -1.62% |
| 2026-09-25 | Rs.1,184.20 | -1.54% | 35,353.29 | +0.18% |
Key Takeaways
Positive Signals: The stock’s early-week surge to new 52-week and all-time highs demonstrated strong underlying momentum, supported by bullish MACD, Bollinger Bands, and OBV indicators. The upgrade to a Buy rating by MarketsMOJO reflected improved financial metrics, including peak operating cash flow and efficient capital utilisation. Valuation metrics improved late in the week, with P/E and EV/EBITDA ratios signalling enhanced price attractiveness relative to peers.
Cautionary Notes: Despite technical upgrades, mixed momentum oscillators such as RSI and KST suggested potential short-term consolidation or pullbacks. The stock’s decline in the latter half of the week, coupled with increased promoter share pledging and a relatively high Debt to EBITDA ratio, highlight risks that investors should monitor. The stock underperformed the Sensex over the full week, indicating some vulnerability amid broader market volatility.
Conclusion
Strides Pharma Science Ltd’s week was characterised by a strong start with record highs and a positive rating upgrade, followed by a retreat amid mixed technical signals and market pressures. The stock’s valuation improvements and robust financial fundamentals provide a solid foundation, but caution remains warranted given the recent price declines and leverage considerations. Overall, the week’s developments underscore the stock’s resilience within the pharmaceuticals sector, balanced by the need for vigilance in a volatile market environment.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
